June 19, 2017 / 3:20 PM / 6 months ago

BRIEF-Wilex says unit Heidelberg Pharma signs research agreement with Takeda

June 19 (Reuters) - WILEX AG:

* SUBSIDIARY HEIDELBERG PHARMA SIGNS EXCLUSIVE MULTI-TARGET RESEARCH AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT OF ANTIBODY TARGETED AMANITIN CONJUGATES

* ‍UNDER TERMS OF AGREEMENT, HEIDELBERG PHARMA WILL PRODUCE ANTIBODY TARGETED AMANITIN CONJUGATES (ATACS) USING ANTIBODIES FROM TAKEDA‘S PROPRIETARY PORTFOLIO FOR UP TO THREE UNDISCLOSED TARGETS​

* ‍UNDER LICENSE AGREEMENT, HEIDELBERG PHARMA WOULD BE ELIGIBLE TO RECEIVE CLINICAL DEVELOPMENT, REGULATORY AND SALES-RELATED MILESTONE PAYMENTS OF UP TO USD 113 MILLION FOR EACH PRODUCT CANDIDATE, AS WELL AS ROYALTIES​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below